Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection
Lun Zhang(National University of Defense Technology), David S. Wishart(University of Alberta), Guoyu Huang, Rashid Ahmed Bux, Claudia Torres-Calzada(University of Alberta), Andrew W. Maksymiuk(The University of Texas MD Anderson Cancer Center), Jean-François Haince, Christian Rolfo(Icahn School of Medicine at Mount Sinai), Philippe Joubert(Institut universitaire de cardiologie et de pneumologie de Québec), Jiamin Zheng(University of Alberta), Rupasri Mandal(University of Alberta), Paramjit S. Tappia(St. Boniface Hospital)
Cited by 4
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
The Human Serum Metabolome
|PLoS ONE|2011|1.7k
1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects
|Journal of Biomolecular NMR|1995|1.6k
DrugBank 6.0: the DrugBank Knowledgebase for 2024
|Nucleic Acids Research|2023|1.4k